NCT05663866 2026-04-13Premedication to Reduce Amivantamab Associated Infusion Related ReactionsJanssen Research & Development, LLCPhase 2 Active not recruiting68 enrolled 12 charts
NCT03589326 2025-11-26A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic LeukemiaTakedaPhase 3 Active not recruiting245 enrolled 15 charts 2 FDA